New York, March 5, 2026, 08:36 EST
- SEC filings revealed that Kenvue executives received new restricted stock unit grants effective March 2.
- The bulk of the awards will vest in three yearly chunks, stretching from 2027 to 2029.
- Kenvue’s disclosures arrive while the company pushes ahead with a planned acquisition by Kimberly-Clark.
Kenvue Inc’s senior leaders just reported fresh equity grants in filings, with the North America chief awarded 127,051 units, as the consumer health company moves closer to a takeover by Kimberly-Clark. .
Kenvue’s filings are drawing attention right now, with the company in the midst of a deal. Kimberly-Clark in November announced plans to buy Kenvue via a cash-and-stock deal, aiming to build out a global health and wellness platform. The companies are shooting for a second-half 2026 close, pending necessary approvals and other conditions. .
Restricted stock units, or RSUs, are a routine piece of compensation. Executives usually have to stick around for the awards to vest before they actually get the shares. The latest grants, disclosed this week, weren’t open-market purchases.
General Counsel Matthew Orlando disclosed receiving 122,286 RSUs, according to the filing, with the shares scheduled to vest in three equal chunks on March 2 of 2027, 2028, and 2029. .
Anindya Dasgupta, who serves as group president for Asia-Pacific, was awarded a 98,994-unit grant, set to vest over three years, a separate filing shows. .
Lawson Carlton, group president for EMEA and Latin America, reported a grant of 93,488 units, with vesting split into three equal portions from 2027 through 2029, according to the filing. .
Michael Wondrasch, Kenvue’s chief tech and data officer, disclosed a grant of 79,407 units with matching vesting dates, according to a filing. .
Heather Howlett, Kenvue’s vice president and chief accounting officer, picked up 22,233 RSUs, according to a filing. Out of that grant, 526 shares were withheld at $18.15 each to handle taxes related to the RSU vesting. .
After dipping for two consecutive days earlier in the week, Kenvue ended March 4 at $18.19, ticking up 0.22%, historical pricing data show. .
Kenvue, which emerged from Johnson & Johnson’s consumer health division, says sharpening execution is its top priority as it pursues the Kimberly-Clark deal. “As we look to 2026, we remain focused on continuing to enhance our performance,” CEO Kirk Perry told investors in February. Company release. Kenvue Investors
Still, the deal’s got baggage: Kenvue is contending with Tylenol litigation that won’t go away. A Texas judge just gave the green light for one lawsuit to move ahead; Kenvue’s response was that it plans to “vigorously defend” itself. Reuters. Reuters
